Selank vs Oxytocin
Both compounds have research-tool applications in the anxiety and social-behaviour research spaces, but with distinctly different mechanism-of-action framing and evidence-base positioning. Selank is a Russian-programme tuftsin-analogue anxiolytic with clinical-trial evidence in generalised anxiety disorder. Oxytocin is the endogenous nonapeptide with foundational significance in the social-cognition research field and licensed obstetric clinical use.
At a glance
| Selank | Oxytocin | |
|---|---|---|
| Structural class | Tuftsin analogue heptapeptide | Endogenous nonapeptide |
| Primary receptor engagement | GABAA receptor allosteric modulation, BDNF induction | Oxytocin receptor (OXTR) |
| Signature research application | Anxiolytic effects, cognitive support in anxiety contexts | Social cognition, trust, pair-bonding, autism spectrum disorder research |
| Route of administration | Intranasal | Intranasal (research) or intravenous (licensed obstetric use) |
| Russian registration | Registered (Vidal.ru): nasal drops | Not assessed |
| UK status | No emc entry found (checked 17 October 2026) | Authorised UK prescription-only medicine (emc) |
| Oxytocin indications (UK SmPC) | Not applicable | Obstetric; intranasal cognitive-endpoint use investigational |
| Evidence base | Multiple Russian clinical trials in generalised anxiety disorder | Substantial international social-cognition research; mixed replicability |
| Evidence tier | B | B |
| Historical foundational context | Russian peptide programme, ACTH-family research heritage | First peptide hormone chemically synthesised (du Vigneaud, 1953 Nobel Prize) |
Research-application positioning
Anxiety-endpoint versus social-cognition-endpoint research
Selank's research-application positioning is primarily in the anxiety-endpoint research space. The compound was developed within the Russian peptide programme as an anxiolytic research tool with the distinctive advantage of anxiolytic effects without the sedation, dependence, or withdrawal issues associated with benzodiazepine anxiolytics. The Russian clinical-trial evidence base includes multiple studies in generalised anxiety disorder populations reporting anxiolytic efficacy comparable to benzodiazepines with a more favourable side-effect profile.
Oxytocin's research-application positioning is in the social-cognition-endpoint research space. The compound is the foundational research tool for the modern social-cognition research field, with substantial international research characterising effects on trust, cooperation, pair-bonding, empathy, and autism-spectrum-disorder-relevant social-behaviour endpoints. The evidence base is broad but with well-documented replicability difficulties that constrain the strength of specific claim-making.
For research designs the two positioning angles are complementary rather than substitutable. Anxiety-endpoint research designs typically select Selank; social-cognition-endpoint research designs typically select Oxytocin. Research designs that need to probe overlap between anxiety and social-behaviour endpoints could draw on both compounds.
Mechanism-of-action framing
GABAergic and BDNF-induction versus oxytocin-receptor engagement
Selank's mechanism-of-action framing operates through multiple angles including GABAA receptor allosteric modulation (contributing to the anxiolytic effects), BDNF induction (contributing to the cognitive-support effects), and enkephalinase inhibition (extending the pharmacodynamic effects). This multi-mechanism framing provides research-tool angles across multiple pathways relevant to anxiety and cognitive-support endpoints.
Oxytocin's mechanism-of-action framing operates through oxytocin receptor (OXTR) engagement. The receptor is expressed on distinct central neuronal populations relevant to social-behaviour neurocircuitry — amygdala, striatum, hypothalamus, and cortical regions — and downstream effects on multiple neurotransmitter systems and cellular-signalling pathways provide the mechanistic substrate for the wide range of social-cognition research findings.
The receptor-engagement specificity difference is substantial. Oxytocin's OXTR engagement is relatively specific; Selank's multi-pathway mechanism is broader. For research-tool selection this specificity difference translates into more focused pharmacology in Oxytocin research applications and broader pharmacology in Selank research applications.